Last reviewed · How we verify

NCT05048524

Peri-operative SLOG for Localized Pancreatic Cancer

Status unknown Phase 2 Last updated 27 March 2024
What this trial tests

Phase 2 trial testing S-1, leucovorin, oxaliplatin and gemcitabine in Pancreatic Ductal Adenocarcinoma in 64 participants. Status unknown.

Timeline
3 September 2021
Primary endpoint
24 August 2024
24 August 2025

Quick facts

Lead sponsorNational Health Research Institutes, Taiwan
PhasePhase 2
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment64
Start date3 September 2021
Primary completion24 August 2024
Estimated completion24 August 2025
Sites3 locations across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

National Health Research Institutes, Taiwan

Who can join

20 and older, any sex, with Pancreatic Ductal Adenocarcinoma or Pancreas Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. To evaluate the efficacy of neoadjuvant chemotherapy SLOG in localized pancreatic cancer 2. To evaluate the safety profile in patients with pancreatic cancer who receive neoadjuvant SLOG 3. To collect tumor tissue and peripheral blood samples from the patients for a comprehensive biomarker evaluation

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

  1. The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study.
    Su YY, Chao YJ, Wang CJ, Liao TK, et al · · 2023 · cited 12× · PMID 37300888 · DOI 10.1097/js9.0000000000000495
  2. Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: a single institution experience.
    Su YY, Ting YL, Wang CJ, Chao YJ, et al · · 2022 · cited 9× · PMID 35693078
  3. Current status and perspectives of genetic testing in gastrointestinal cancer (Review).
    Matsuoka T, Yashiro M. · · 2024 · cited 4× · PMID 38058469 · DOI 10.3892/ol.2023.14155
  4. Single-cell RNA sequencing: enhancing the predictive accuracy of tumor immunotherapy efficacy.
    Zhou W, Huang Z, Wu Z, Tang M, et al · · 2025 · cited 3× · PMID 40857744 · DOI 10.1042/ebc20253017

Verify or expand the search:

Other recruiting trials for Pancreatic Ductal Adenocarcinoma

Currently open trials in the same condition.

Other National Health Research Institutes, Taiwan trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05048524.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing